Shareholder Derivative

     NASHVILLE - Directors of Provectus Biopharmaceuticals misrepresented the status of its primary product, a melanoma drug, and the share price fell from $5.22 to 73 cents after the truth came out, shareholders claim in a federal derivative complaint.